Cytosin-Arabinosid
Childhood B Acute Lymphoblastic Leukemia
St. Jude Children's Research HospitalPhase 3Dormant
BBB
78/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Childhood B Acute Lymphoblastic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
VINCRISTINE SULFATE St. Jude Children's Research Hospital | Phase 3 | A |
MERCAPTOPURINE ANHYDROUS St. Jude Children's Research Hospital | Phase 3 | A |
PEGASPARGASE St. Jude Children's Research Hospital | Phase 3 | A |
Cyclophosphamide St. Jude Children's Research Hospital | Phase 3 | BBB |
METHOTREXATE St. Jude Children's Research Hospital | Phase 3 | BBB |
View all 44 →
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →